1609655-49-3

1609655-49-3 structure

Name: Ziv-aflibercept
Chemical Name: Ziv-aflibercept
CAS Number: 1609655-49-3
Molecular Formula:
Molecular Weight:
Catalog: Signaling Pathways Protein Tyrosine Kinase/RTK VEGFR
Create Date: 2023-04-20 19:11:32
Modify Date: 2024-01-14 13:37:50
Ziv-aflibercept is a soluble inhibitor of vascular endothelial growth factor (VEGF). Ziv-aflibercept is an adaptive variant of Aflibercept (HY-108801), Ziv-aflibercept has a low PH value and high osmotic pressure when compared to Aflibercept. Ziv-aflibercept has potential applications in metastatic colorectal carcinoma and retinal diseases[1][2].

Name	Ziv-aflibercept

Description	Ziv-aflibercept is a soluble inhibitor of vascular endothelial growth factor (VEGF). Ziv-aflibercept is an adaptive variant of Aflibercept (HY-108801), Ziv-aflibercept has a low PH value and high osmotic pressure when compared to Aflibercept. Ziv-aflibercept has potential applications in metastatic colorectal carcinoma and retinal diseases[1][2].
Related Catalog	Research Areas >> Cancer Research Areas >> Cardiovascular Disease Signaling Pathways >> Protein Tyrosine Kinase/RTK >> VEGFR
In Vitro	Ziv-aflibercept (0.25、0.5、1.0 和 5 mg/mL；24 h) 以剂量依赖性方式降低 ARPE-19 细胞的线粒体膜电位[1]。 Cell Viability Assay[1] Cell Line: ARPE-19 cells. Concentration: 0.25, 0.5, 1.0 and 5 mg/mL. Incubation Time: 24 h. Result: Insignificantly affected cell viability (below 1 mg/mL).
In Vivo	Ziv-aflibercept (25 mg/mL；眼内注射；单剂量) 在兔子右眼中没有显著引起白内障、视网膜脱离等相关并发症[2]。
References	[1]. Malik D, et al. Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture. Br J Ophthalmol. 2014 Jun;98 Suppl 1(Suppl 1):i11-16. [2]. de Oliveira Dias JR, et al. Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept. Int J Retina Vitreous. 2016 Feb 1;2:3.

No Any Chemical & Physical Properties